CRL Stock Forecast & Price Target

Charles River is positioned favorably because management’s 2030 framework points to 5%–7% organic revenue growth and low-double-digit adjusted EPS growth, with the latest 2026/2027 adjusted EPS estimates at $11.42/$12.84. The core upside lies in Discovery & Safety Assessment, where pricing, automation, BioAnalysis expansion, and operational savings could lift margins while demand is already improving, as shown by a 1.19x DSA book-to-bill and nearly 10% year-over-year proposal growth. Manufacturing also supports the bullish view through a higher-quality post-CDMO portfolio, with 7%–9% organic growth, >40% adjusted operating margins, and recurring microbial revenue helping offset near-term refinancing costs.

Charles River is facing a negative fundamental setup because demand for preclinical safety and IND-enabling studies could remain weak if biopharma funding, pipeline activity, and biotech capital availability do not improve, limiting growth across RMS, DSA, and Manufacturing. The company also faces structural pressure from faster-than-expected adoption of NAMs, which could erode its highest-margin DSA business, while its limited ~$120M NAMs exposure leaves it poorly positioned to offset animal-study declines. In addition, margin expansion depends on K.F. (Cambodia) integration and lower NHP procurement costs, yet execution risk, cost inflation, and geopolitical disruptions could prevent the expected $16M in 2026 and $39M in 2027 EPS accretion.